Eylea 2 MG/0.05 ML syringe 0.05ML
Ended Awarded
- Contract number
- SPE2DB26FX1KJ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,224
Award facts
- Contract value 100% obligated
- $34,224.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $34,224.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA 2 mg/0.05 mL syringes. The award was issued on October 27, 2025, with an ultimate completion date of November 18, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a comprehensive $30.3 billion acquisition strategy designed to supply pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group serves as a critical regional prime vendor contractor under the PPV-G GEN V initiative, which features a $499.9 billion ceiling contract extending through December 31, 2036, with a 30-month base period and three 30-month option periods. The contractor maintains an extensive product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals to support recurring medical supply needs across the global military healthcare system. The company's demonstrated performance on numerous prior delivery orders and its established presence in the federal pharmaceutical supply chain since 2001 position it as a qualified supplier capable of fulfilling the diverse and specialized pharmaceutical requirements of Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DB26FX1KJ?
SPE2DB26FX1KJ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FX1KJ worth?
The government has obligated $34,224 on SPE2DB26FX1KJ.
Is contract SPE2DB26FX1KJ an order under another contract?
Yes. SPE2DB26FX1KJ is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1KJ competed?
The extent of competition for SPE2DB26FX1KJ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award